Aran Singanayagam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2322098/publications.pdf

Version: 2024-02-01

		168829	139680
66	4,030	31	61
papers	citations	h-index	g-index

74	74	74	7205
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. Nature Communications, 2022, 13, 1609.	5.8	24
2	Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease. Journal of Clinical Investigation, 2022, 132, .	3.9	27
3	Impaired Humoral and Cellular Responses to COVID-19 Vaccine in Heart and Lung Transplant Recipients. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1476-1479.	2.5	4
4	Down to a T: The Functional Importance of Lymphopenia in Severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	1
5	The respiratory tract microbiome: moving from correlation to causation. European Respiratory Journal, 2022, 59, 2103079.	3.1	5
6	Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. Journal of Allergy and Clinical Immunology, 2021, 147, 510-519.e5.	1.5	121
7	Reply. Journal of Allergy and Clinical Immunology, 2021, 147, 1117-1118.	1.5	1
8	Gateway to the lungs: Viral entry receptors and susceptibility to COVID â€19. Respirology, 2021, 26, 404-405.	1.3	1
9	Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 344-356.	1.4	13
10	Asthma and viruses: AÂfocus on rhinoviruses and SARS-CoV-2. Journal of Allergy and Clinical Immunology, 2021, 147, 1648-1651.	1.5	5
11	Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1075-1085.	2.5	13
12	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Annals of the Rheumatic Diseases, 2021, 80, 1322-1329.	0.5	188
13	Our evolving view of neutrophils in defining the pathology of chronic lung disease. Immunology, 2021, 164, 701-721.	2.0	21
14	Repurposing Existing Drugs for the Treatment of COVID-19. Annals of the American Thoracic Society, 2020, 17, 1186-1194.	1.5	19
15	Why asthma might surprisingly protect against poor outcomes in COVID-19. European Respiratory Journal, 2020, 56, 2003045.	3.1	30
16	Metagenomic Characterization of the Respiratory Microbiome. A PiÃ¨ce de RÃ©sistance. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 321-322.	2.5	5
17	Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?. Lancet, The, 2020, 395, 1111.	6.3	247
18	Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): Review of mechanisms that underlie risks. Journal of Allergy and Clinical Immunology, 2020, 146, 1292-1294.	1.5	17

#	Article	IF	Citations
19	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax, 2020, 75, 520-527.	2.7	97
20	Beclomethasone Has Lesser Suppressive Effects on Inflammation and Antibacterial Immunity Than Fluticasone or Budesonide in Experimental Infection Models. Chest, 2020, 158, 947-951.	0.4	5
21	Respiratory Virus Infections in Asthma: Research Developments and Therapeutic Advances. Acta Medica Academica, 2020, 49, 130-143.	0.3	9
22	Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyteâ€“dendritic cell antigen presentation. Science Immunology, 2019, 4, .	5.6	53
23	Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Science Translational Medicine, 2019, 11, .	5.8	75
24	Antiviral immunity is impaired in COPD patients with frequent exacerbations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L893-L903.	1.3	57
25	Not just the common cold: Rhinovirus infection in lung allograft recipients. Respirology, 2019, 24, 1134-1135.	1.3	0
26	Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations . International Journal of COPD, 2019, Volume 14, 823-833.	0.9	13
27	Less burn, more fat: electronic cigarettes and pulmonary lipid homeostasis. Journal of Clinical Investigation, 2019, 129, 4077-4079.	3.9	5
28	Î²₂-Agonists Enhance Asthma-Relevant Inflammatory Mediators in Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 128-132.	1.4	17
29	Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 142, 815-823.e6.	1.5	63
30	Severe Disseminated Infection with Emerging Lineage of Methicillin-Sensitive Staphylococcus aureus. Emerging Infectious Diseases, 2018, 25, 187-189.	2.0	3
31	Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications, 2018, 9, 2229.	5.8	153
32	Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study. Pneumonia (Nathan Qld), 2017, 9, 2.	2.5	2
33	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. European Respiratory Journal, 2017, 50, 1602306.	3.1	5
34	Role of microbiome in the pathophysiology and disease course of asthma. Current Opinion in Pulmonary Medicine, 2017, 23, 41-47.	1.2	33
35	Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. Journal of Infection, 2016, 73, 45-53.	1.7	60
36	Screening tests for tuberculosis before starting biological therapy. BMJ, The, 2015, 350, h1060-h1060.	3.0	12

#	Article	IF	Citations
37	A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD. Clinical Science, 2015, 129, 245-258.	1.8	38
38	Screening for latent tuberculosis before tumour necrosis factor antagonist therapy. European Respiratory Journal, 2015, 45, 1510-1512.	3.1	4
39	Antibiotic treatment in exacerbations of chronic obstructive pulmonary disease: recent trial results. Clinical Investigation, 2015, 5, 189-204.	0.0	0
40	Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respiratory Medicine,the, 2014, 2, 919-932.	5.2	68
41	Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax, 2014, 69, 609-615.	2.7	99
42	Risk Factors for Aspiration in Community-acquired Pneumonia: Analysis of a Hospitalized UK Cohort. American Journal of Medicine, 2013, 126, 995-1001.	0.6	95
43	Exhaled breath acetone for therapeutic monitoring in pneumonia using selected ion flow tube mass spectrometry (SIFT-MS). Analytical Methods, 2013, 5, 3807.	1.3	15
44	Predictors of Mortality in Hospitalized Adults with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2013, 10, 81-89.	1.5	203
45	Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respiratory Medicine,the, 2013, 1, 653-662.	5.2	29
46	Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, The, 2013, 346, f1235-f1235.	3.0	101
47	Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-Î± antagonist therapy. Thorax, 2013, 68, 955-961.	2.7	29
48	Obesity is associated with improved survival in community-acquired pneumonia. European Respiratory Journal, 2013, 42, 180-187.	3.1	65
49	Virusâ€“bacteria interactions in COPD exacerbations. , 2013, , 76-83.		2
50	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 653-659.	2.5	44
51	Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Medicine, 2012, 10, 27.	2.3	67
52	Lung microbiology and exacerbations in COPD. International Journal of COPD, 2012, 7, 555.	0.9	101
53	Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: Implications for triage in primary and secondary care. Journal of Infection, 2011, 63, 243-251.	1.7	28
54	Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Medicine, 2011, 37, 1409-1420.	3.9	134

#	Article	IF	Citations
55	Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 416-423.	1.3	45
56	Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study. Clinical Infectious Diseases, 2011, 53, 107-113.	2.9	231
57	Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients Without Major Criteria or Contraindications to Intensive Care Unit Care. Clinical Infectious Diseases, 2011, 53, 503-511.	2.9	131
58	Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax, 2010, 65, 878-883.	2.7	262
59	Diagnostic accuracy, safety and utilisation of respiratory physician-delivered thoracic ultrasound. Thorax, 2010, 65, 449-453.	2.7	66
60	Incidence and Prognostic Implications of Acute Kidney Injury on Admission in Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 825-832.	0.4	65
61	Right ventricular dilation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism. Respiratory Medicine, 2010, 104, 1057-1062.	1.3	23
62	Admission D-dimer Can Identify Low-Risk Patients With Community-Acquired Pneumonia. Annals of Emergency Medicine, 2009, 53, 633-638.	0.3	57
63	Budesonide and risk of pneumonia. Lancet, The, 2009, 374, 2050.	6.3	4
64	C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 219-225.	0.6	303
65	Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 1002-1007.e1.	0.6	159
66	Predicting the Need for Mechanical Ventilation and/or Inotropic Support for Young Adults Admitted to the Hospital with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 1571-1574.	2.9	67